Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Deal Details

C/PIndustryStatusTicker(s)Issuer(s)Size(m)TranchesRegionDate
HYC
HLTH
PRCD
BIOGRP
CAB Selas€800
1EMEA
Jan 28, 2021
currency
EUR
size (m)
800.000
maturity
Feb 1, 2028
type
Fixed
tenor
7.000
call
3
registration
144A/Reg S
benchmark
DBR
ranking
Sr. Secured
moody's
B2
s&p
B-
fitch
B+
size description
-
re-open/tap
No
ipt
mid to high 3s
ipt-pxd
-
guidance
3.25%-3.50%
spread
409
coupon
3.375%
spread set
-
price
100.00000
yield
3.375%
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
BNP, CAG, CTI, DEU, ...
joint leads
-
passive leads
-
co-managers
-
coordinating managers
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
BNP, CAG, CTI, DEU, ...
joint leads
-
passive leads
-
co-managers
-
coordinating managers
Tranche Comments
Redemption: 2024-02-01; Registration: 144A/Reg S;
Deal Comments
Biogroup (BIOGRP) EUR1.05bn (up from EUR1bn) 144A/Reg S 2-part. Via JPM (B&D)/BNP/Natixis joint glocos/Citi/CA/DB/GS/HSBC joint books. List Lux. NY law. Settles 02/09. New term loan size reduced by EUR50m to EUR1.45bn. - CAB EUR800m (up from EUR750m) sr sec notes due 02/01/28 (7y). NC3 (MWC B+50bp), then at 101.688, 100.844, 100. Equity claw: 3y 40% at 103.375. Special call: 10% per year the 1st 3 years at 103. B2/B-/B+ (negative/stable/stable). IPT mid to high 3s. Px talk: 3.25%-3.50%. Final terms: EUR800m at 3.375%. Priced:3.375% at 100. +409bp vs DBR 0.5% 02/15/28. - Laboratoire Eimer EUR250m sr notes due 02/01/29 (8y). NC3 (MWC B+50bp), then at 102.50, 101.25, 100. Equity claw: 3y 40% at 105.00. Caa1/CCC/CCC+ (negative/stable/stable). Reg S ISIN: XS2294187690. IPT mid 5s. Px talk: 5.00%-5.25%. Final terms: EUR250m at 5.00%. Priced: 5.00% at 100. +567bp vs DBR 0.25% 02/15/29. Did investor call at 10am UKT 01/25. Virtual meetings available through 01/27. Books closed at 10am UKT 01/28. UOP: along with a new EUR1.45bn (down from EUR1.5bn) term loan and EUR80m cash on hand, to repay its existing EUR2.015bn term loan, existing EUR305m 2nd lien debt and existing EUR219m PIK notes. Biz: Leading private medical laboratory testing business in France and Belgium.

Commentary

Explore all other Commentary & Deal Flow

Deal Flow

Explore all other Commentary & Deal Flow
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.